FDA Launches Real-Time Clinical Trial Program; Lilly and AbbVie Secure Multi-Billion Dollar Pipeline Deals, Including KST-6051
FDA Accelerates New Drug Approvals with Real-Time Clinical Trials
The U.S. Food and Drug Administration (FDA) has announced a pilot program for Real-Time Clinical Trials (RTCT) to expedite new drug development by enabling real-time data review. AstraZeneca (AZN) and Amgen (AMGN) are participating in proof-of-concept (PoC) trials in the oncology field. AstraZeneca is conducting a Phase 2 trial of Calquence (acalabrutinib) in combination therapy for mantle cell lymphoma (MCL), while Amgen is sharing Phase 1b clinical data for Imdelltra (tarlatamab) for small cell lung cancer (SCLC) with regulatory authorities in real-time. This initiative allows regulators to immediately monitor clinical endpoints and safety signals, potentially accelerating new drug approvals.
Eli Lilly Enters Multi-Billion Dollar AI-Driven Gene Editing Partnership
Eli Lilly (LLY) has entered into a gene therapy development partnership with AI-based startup Profluent, valued at up to $2.25 billion. Profluent uses AI models to design customized recombinases that insert long DNA sequences into specific target sites within the genome. Eli Lilly will gain exclusive commercialization rights, significantly expanding its next-generation gene editing technology portfolio. While the upfront payment is undisclosed, this collaboration reflects a trend of major pharmaceutical companies actively investing in AI partnerships to gain a leading position in the gene editing market.
Pfizer Reports Positive Phase 3 Results for Elrexfio in Multiple Myeloma
Pfizer (PFE) announced positive results from a Phase 3 clinical trial of its multiple myeloma treatment, Elrexfio (elranatamab). Elrexfio, a bispecific antibody, demonstrated a statistically significant improvement in progression-free survival (mPFS) compared to Darzalex and Pomalyst combination therapy, meeting the primary endpoint. This positive data paves the way for Elrexfio to expand its approval to earlier lines of therapy, potentially capturing a larger share of the approximately $24 billion multiple myeloma market and strengthening its competitive position against drugs like Tecvayli.
AbbVie Secures Option to Acquire Kestrel Therapeutics for Pan-KRAS Inhibitor KST-6051
AbbVie (ABBV) has entered into an exclusive option agreement to acquire Kestrel Therapeutics for up to $1.45 billion. AbbVie will fund clinical development of Kestrel's pan-KRAS inhibitor, KST-6051. KST-6051, which has entered Phase 1 clinical trials, exhibits a differentiated mechanism of action (MoA) by binding to both the active and inactive conformations of KRAS. This approach has the potential to overcome resistance mechanisms seen with existing G12C-targeted therapies, offering a broader therapeutic window and potentially becoming a game-changer in the next-generation solid tumor market.
The FDA's launch of the Real-Time Clinical Trial (RTCT) pilot program and Eli Lilly's (LLY) $2.25 billion partnership with Profluent are expected to increase the speed and efficiency of clinical development for AI-driven innovative new drugs, which will reduce regulatory risks for biotech companies in the short term. AbbVie's (ABBV) $1.45 billion acquisition of Kestrel Therapeutics and its pan-KRAS inhibitor KST-6051, which recently entered Phase 1 clinical trials, suggests the possibility of overcoming resistance to existing G12C-targeted therapies such as Lumakras, and signals a potential shift in the long-term solid tumor market. With Pfizer's (PFE) Elrexfio achieving its primary endpoints in a Phase 3 trial, the company is poised to proactively expand its market share in the approximately $24 billion global multiple myeloma market, competing against J&J's Tecvayli. These pipeline expansions and regulatory innovations by multinational pharmaceutical companies are expected to accelerate clinical development and the adoption of AI platforms, which will lead to a paradigm shift in drug design for researchers and create more exit opportunities for investors in high-value target areas.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/fda-real-time-trials-abbvie-kestrel-lilly-profluent/818719/